Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Journal:

Annals of the Rheumatic Diseases

Published:

2025-09-18

DOI:

10.1016/j.ard.2025.08.006

Affiliations:

12

Authors:

12

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	5.500000	0.46
Janssen Inc., Canada	1.000000	0.08
Memorial University of Newfoundland (MUN), Canada	1.000000	0.08
University of Rochester Medical Center (URMC), UR, United States of America (USA)	1.000000	0.08
Leiden University Medical Center (LUMC), Netherlands	1.000000	0.08
University of Oxford, United Kingdom (UK)	1.000000	0.08
Swedish Health Services, United States of America (USA)	0.500000	0.04
UW Medicine, United States of America (USA)	0.500000	0.04
Drexel University, United States of America (USA)	0.500000	0.04

Interested in Clinical Sciences?